Relief Therapeutics and NeuroRx Sign Manufacturing Agreements for COVID-19 Drug

October 1, 2020

Relief Therapeutics and NeuroRx have entered into an agreement with Bachem Americas to supply enough of their investigational COVID-19 treatment RLF-100 (aviptadil) to treat 1 million COVID-19 patients. 

The companies also signed a separate agreement with Nephron to manufacture commercial supplies of RLF-100 that will be immediately available should clinical trials demonstrate the drug’s safety and efficacy.

RLF-100 is in late-stage testing in the U.S. for treating critically ill COVID-19 patients, and results from that trial are expected next month. The partners plan to begin European trials of the drug in the first quarter of 2021.

View today's stories